{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:58:15Z","timestamp":1791863895146,"version":"4.3.4"},"reference-count":44,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,12,27]],"date-time":"2011-12-27T00:00:00Z","timestamp":1324944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Dopaminergic hypofunction and hyperprolactinaemia have been implicated in the pathogenesis of obesity and glucose intolerance. The aim of this pilot study was to determine the efficacy of cabergoline, a dopamine receptor agonist, on body weight and glucose tolerance in obese non\u2010diabetic persons with normal plasma prolactin levels.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    This 16\u2010week double blind, placebo\u2010controlled pilot study randomized non\u2010diabetic obese adults (body mass index 30\u201342 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) to placebo or cabergoline (0.25 mg twice weekly for 4 weeks followed by 0.5 mg twice weekly for the next 12 weeks). Of 40 subjects enrolled, 29 completed 16 weeks: 16 randomized to placebo and 13 to cabergoline. All subjects were counselled on a 500 kcal\/day calorie deficit diet. A 75\u2010g oral glucose tolerance test was performed at baseline and at 16 weeks.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    As expected, prolactin levels decreased after cabergoline (p &lt; 0.001). Weight loss was similar after placebo compared with cabergoline treatment: 1.0 vs. 1.2% body weight, respectively. Fasting glucose levels did not differ between groups after treatment, however, 90\u2010min postprandial glucose and insulin decreased in the cabergoline group only (p = 0.029). HOMA\u2010IR (homeostasis model of assessment) increased by 40% after placebo and 1.5% after cabergoline treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    This pilot study suggests that cabergoline therapy may improve glucose tolerance independent of weight loss, however, a larger, longer term study of dopamine receptor agonist therapy in obese individuals is warranted to confirm this finding.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2011.01534.x","type":"journal-article","created":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T13:29:21Z","timestamp":1320931761000},"page":"335-340","source":"Crossref","is-referenced-by-count":44,"title":["Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults"],"prefix":"10.1111","volume":"14","author":[{"given":"C. D.","family":"Gibson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Karmally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Wardlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Korner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,27]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2010.07.005"},{"key":"e_1_2_7_3_2","first-page":"R1365","article-title":"Dysregulation of arcuate nucleus preproneuropeptide Y mRNA in diet\u2010induced obese rats.","volume":"272","author":"Levin BE","year":"1997","journal-title":"Am J Physiol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2105-10.2010"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03643-6"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1995.tb00221.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-002-0072-8"},{"issue":"7","key":"e_1_2_7_8_2","first-page":"22","article-title":"Antipsychotic\u2010induced weight gain: a review of the literature.","volume":"62","author":"Allison DB","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0022-3565(25)30867-0","article-title":"Effects of dopaminergic agonists and antagonists of feeding in intact and 6\u2010hydroxydopamine\u2010treated rats.","volume":"201","author":"Heffner TG","year":"1977","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0809"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1530423"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)49291-5"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00403.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1470077"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2826.2003.01092.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000054522"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1018"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K06-026"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032184"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000054344"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000054415"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2005.18.9.921"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSOTT.S9575"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01930467"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1697"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.6.667"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01304.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1380286"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311403"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0277-9"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.150"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.46"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.10.1683"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.8.1154"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000078932"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.7.1039"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-008-0097-3"},{"key":"e_1_2_7_39_2","first-page":"392","article-title":"Prolactinoma and body weight: a retrospective study.","volume":"125","author":"Creemers LB","year":"1991","journal-title":"Acta Endocrinol"},{"key":"e_1_2_7_40_2","unstructured":"USFDA.Cycloset prescribing information.Available from URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020866s002lbl.pdf. Accessed 21 December 2011."},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.7.1087"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012512"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2009"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062222"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054830"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2011.01534.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2011.01534.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:39:36Z","timestamp":1761867576000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2011.01534.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,27]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1463-1326.2011.01534.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01534.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,27]]}}}